Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 20 Jan 2018 Results assessing Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Jan 2018 Primary endpoint has not been met. (Correlation between plasma VEGF-A level and progression free survival), as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium